CH678918A5 - - Google Patents

Download PDF

Info

Publication number
CH678918A5
CH678918A5 CH819/89A CH81989A CH678918A5 CH 678918 A5 CH678918 A5 CH 678918A5 CH 819/89 A CH819/89 A CH 819/89A CH 81989 A CH81989 A CH 81989A CH 678918 A5 CH678918 A5 CH 678918A5
Authority
CH
Switzerland
Prior art keywords
lysine
mol
fatty acids
virus
epa
Prior art date
Application number
CH819/89A
Other languages
German (de)
English (en)
Inventor
Nagy Peter Dr Literati
Maria Dr Boros
Jenoe Dr Szilbereky
Istvan Dr Racz
Gyoengyver Dr Soos
Miklos Dr Koller
Alan Dr Pinter
Gabor Nemeth
Original Assignee
Biorex Kft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biorex Kft filed Critical Biorex Kft
Publication of CH678918A5 publication Critical patent/CH678918A5/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CH819/89A 1988-03-09 1989-03-06 CH678918A5 (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
HU881132A HU209973B (en) 1988-03-09 1988-03-09 Process for production of antiviral and immunstimular pharmaceutical composition

Publications (1)

Publication Number Publication Date
CH678918A5 true CH678918A5 (pt) 1991-11-29

Family

ID=10952974

Family Applications (1)

Application Number Title Priority Date Filing Date
CH819/89A CH678918A5 (pt) 1988-03-09 1989-03-06

Country Status (14)

Country Link
JP (1) JPH01316316A (pt)
KR (1) KR890014103A (pt)
BE (1) BE1002890A3 (pt)
CA (1) CA1334576C (pt)
CH (1) CH678918A5 (pt)
DE (1) DE3907649C2 (pt)
FI (1) FI94591C (pt)
FR (1) FR2628324B1 (pt)
GB (1) GB2216418B (pt)
HU (1) HU209973B (pt)
IT (1) IT1229562B (pt)
LU (1) LU87471A1 (pt)
NL (1) NL8900574A (pt)
SE (1) SE8900828L (pt)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0641562A1 (en) * 1993-09-08 1995-03-08 Sandoz Nutrition Ltd. Nutritional supplement

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU210122B (en) * 1988-03-23 1995-02-28 Biorex Kutato Fejlesztoe Kft Process for production of composition against thromboembolytic conditions of circulating system and heart
JPH04279523A (ja) * 1991-01-11 1992-10-05 Nisshin Flour Milling Co Ltd 免疫賦活油脂加工品
GB9304746D0 (en) * 1993-03-09 1993-04-28 Scotia Holdings Plc Treatment of viral infections
EP0690709A1 (en) * 1993-03-26 1996-01-10 DINU, Constantin Romulus Pharmaceutical composition for the treatment of certain viruses and autoimmune diseases and the procedure of its preparation
US5767156A (en) * 1993-10-06 1998-06-16 Peptide Technology Limited Polyunsaturated fatty acids and uses thereof
IT1264987B1 (it) * 1993-12-14 1996-10-17 Prospa Bv Sali di un acido grasso poliinsaturo e formulazioni farmaceutiche che li contengono
AUPM906594A0 (en) * 1994-10-26 1994-11-17 Peptide Technology Limited Synthetic polyunsaturated fatty acid analogues
DE19503993A1 (de) * 1995-02-08 1996-08-14 Johann Friedrich Dr Med Desaga Verwendung eines Produktes zur enteralen Versorgung mit Lebensmittelinhaltsstoffen oder Arzneimittelinhaltsstoffen
US5639858A (en) * 1995-03-22 1997-06-17 Tularik, Inc. Human signal transducer and binding assays
WO1996030381A1 (en) * 1995-03-28 1996-10-03 Novo Nordisk A/S Immunosuppressive agents
HU227588B1 (hu) 2004-12-03 2011-09-28 Sinnex Mueszaki Fejlesztoe Es Tanacsado Kft Többszörösen telítetlen zsírsavak észtereit tartalmazó vírusellenes és immunstimuláns gyógyászati készítmény
EP2219639A1 (en) * 2007-12-17 2010-08-25 University of Florida Research Foundation, Inc. Materials and methods for treatment of pathological ocular vascular proliferation
FR3031451B1 (fr) * 2015-01-13 2018-03-23 Greentech Sel d'un triglyceride, preparation et utilisations
EP3463310B1 (en) * 2016-05-25 2023-07-05 Evonik Operations GmbH Tablets with high active ingredient content of omega-3 fatty acid amino acid salts
EP3248467A1 (de) * 2016-05-25 2017-11-29 Evonik Technochemie GmbH Verfahren zur herstellung einer zusammensetzung enthaltend omega-3-fettsäure-l-lysin-salze
WO2019008101A1 (en) 2017-07-06 2019-01-10 Evonik Technochemie Gmbh ENTERICALLY COATED SOLID DOSAGE FORM COMPRISING AMINO ACIDS SALTS OF OMEGA-3 FATTY ACIDS
AU2018317802B2 (en) 2017-08-15 2024-04-04 Evonik Operations Gmbh Tablets with high active ingredient content of omega-3 fatty acid amino acid salts
BR112022002129A2 (pt) 2019-08-08 2022-04-19 Evonik Operations Gmbh Processo a jusante para a produção de sais de ácidos graxos poli-insaturados
US20220287345A1 (en) 2019-08-08 2022-09-15 Evonik Operations Gmbh Solubility enhancement of poorly soluble actives
DE102022003441A1 (de) 2022-09-17 2024-03-28 Jutta Ibrahim Nahrungsergänzungsmittel Omega3 und essentielle Aminosäure(n)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1256162A (en) * 1968-08-16 1971-12-08 Braun Fa B Improvements in and relating to liquid products for intravenous administration
FR2215212B1 (pt) * 1973-01-18 1976-03-05 Seperic Ch
FR2508797B1 (fr) * 1981-07-03 1986-03-14 Charles Chany Medicament comprenant le produit de la reaction d'un acide carboxylique en c1 a c6 sur un amino-acide basique
GB2118437B (en) * 1982-03-01 1984-12-12 Efamol Ltd Composition for treating alcoholism
US4513008A (en) * 1982-07-30 1985-04-23 The Vinoxen Company, Inc. Virucidal compositions and therapy
DE3229956A1 (de) * 1982-08-12 1984-02-16 Erichsen, Friedrich Karl, Dr., 2351 Schillsdorf Arzneimittel mit cytostatischer wirkung
DE3514328C1 (de) * 1985-04-19 1986-09-11 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts, 6900 Heidelberg Verwendung von L-Ornithin bei der selektiven Hemmung von cytotoxischen T-Lymphozyten-Effektorzellen
WO1988001861A1 (en) * 1986-09-17 1988-03-24 Baxter Travenol Laboratories, Inc. Nutritional support or therapy for individuals at risk or under treatment for atherosclerotic, vascular, cardiovascular, and/or thrombotic diseases
AU1489688A (en) * 1987-02-20 1988-09-14 Shriners Hospitals For Crippled Children Omega-3 fatty acids in traumatic injury treatment
DE3726299A1 (de) * 1987-06-26 1989-02-23 Dietl Hans Fettemulsion zur intravenoesen anwendung

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0641562A1 (en) * 1993-09-08 1995-03-08 Sandoz Nutrition Ltd. Nutritional supplement

Also Published As

Publication number Publication date
FI94591B (fi) 1995-06-30
FR2628324B1 (fr) 1994-05-27
KR890014103A (ko) 1989-10-21
HU209973B (en) 1995-01-30
FI94591C (fi) 1995-10-10
SE8900828L (sv) 1989-09-10
JPH01316316A (ja) 1989-12-21
FI891145A0 (fi) 1989-03-09
DE3907649C2 (de) 1996-07-11
BE1002890A3 (fr) 1991-07-16
IT8919704A0 (it) 1989-03-09
DE3907649A1 (de) 1989-09-28
GB2216418B (en) 1991-12-11
FR2628324A1 (fr) 1989-09-15
GB2216418A (en) 1989-10-11
IT1229562B (it) 1991-09-04
LU87471A1 (fr) 1990-10-02
HUT60432A (en) 1992-09-28
NL8900574A (nl) 1989-10-02
GB8905385D0 (en) 1989-04-19
SE8900828D0 (sv) 1989-03-09
FI891145A (fi) 1989-09-10
CA1334576C (en) 1995-02-28

Similar Documents

Publication Publication Date Title
CH678918A5 (pt)
DE69100724T2 (de) Zusammensetzungen essentieller Fettsäuren und Therapie.
DE69031033T2 (de) Verwendung von eicosapentaensäure zur behandlung der kachexie
DE60026826T2 (de) Alterungsschutztetrapeptid, dieses enthaltende pharmazeutische zusammensetzungen und seine verwendung
DE69730330T2 (de) Verwendung von l-acetylcarnitin, l-isovalerylcarnitin oder l-propionyl-carnitin zur steigerung des igf-spiegels
DE69022678T2 (de) S(+)-Ibuprofen-L-Aminosäure und S(+)-Ibuprofen-D-Aminosäure als Analgetika mit grösserem pharmakologischem Potential.
DE3774449D1 (de) Pharmazeutische zusammensetzungen.
FR2439187A1 (fr) Derives de 1-piperazine-carboxamides et -carbothioamides substitues, procede de preparation et compositions pharmaceutiques les contenant
EP0203580A2 (de) Gamma-IFN als Wirkstoff zur Hemmung (Verhinderung) von Abbauprozessen im Knochen
JP4700808B2 (ja) フルボ酸、および種々の状態の処置におけるその使用
DE3334323A1 (de) Prophylaktische substanz oder zusammensetzung
AT398073B (de) Antiviral und immunstimulierend wirkende neue salze, sowie verfahren zu deren herstellung und verwendung der salze
EP0246734B1 (en) Iron-containing composition and method for treatment of cancer
US5246726A (en) Iron-containing composition and method for treatment of cancer
US4256743A (en) Inhibition of bone resorption with H1 -blocking antihistamines
DE69733778T2 (de) Langkettige alkohole, alkane, fettsäuren und amide als vireninhibitoren
EP0165274A1 (de) Verwendung von cystein-derivaten oder deren salzen, zur steigerung der insulinsekretion der langerhans'schen inseln der bauchspeicheldrüse.
DE69433583T2 (de) Zubereitungen auf Basis von Padina Algen oder ihrer Extrakten, und ihre pharmazeutische, Nährungsmittel oder für die Kultur von Mollusken oder Arthropoden Kulturverwendungen
DE1667903C3 (de) Verwendung von Cysteinderivaten zur Herstellung von per oral verabreichbaren Mitteln zur Bekämpfung der Seborrhoe
DE602004002292T2 (de) Zusammensetzungen enthaltend eine superoxiddismutase, einen 5-lipoxygenase-inhibitor sowie deren verwendung
EP0403575A1 (de) Acyl-carnitin zur behandlung und zur verhütung von virusinfektionen.
DE3780702T2 (de) Verwendung von etodolac zur senkung des blutgehalts an harnsaeure.
DE3627759A1 (de) Pharmazeutische zusammensetzung zum inaktivieren bakterieller endotoxine
DE1767275C3 (de) Verwendung von 2-Thio-4-uracilcarbonsäure und 4-Uracilcarbonsäure
CH675538A5 (pt)

Legal Events

Date Code Title Description
PL Patent ceased